DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Romiplostim is an investigational drug.
There have been 30 clinical trials for Romiplostim. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2016.
The most common disease conditions in clinical trials are Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, and Preleukemia. The leading clinical trial sponsors are Amgen, Kyowa Hakko Kirin China Pharmaceutical Co.,LTD., and Assistance Publique - Hôpitaux de Paris.
There are eight hundred and seventeen US patents protecting this investigational drug and eight international patents.
Recent Clinical Trials for Romiplostim
|Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer||Amgen||Phase 3|
|Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia||Kyowa Kirin Co., Ltd.||Phase 2/Phase 3|
|Study of AMG531(Romiplostim) in Patients With Aplastic Anemia||Kyowa Hakko Kirin Co., Ltd||Phase 2/Phase 3|
Top disease conditions for Romiplostim
Top clinical trial sponsors for Romiplostim
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Romiplostim||See Pricing||Compounds and their methods of use||Agios Pharmaceuticals, Inc. (Cambridge, MA)||See Pricing|
|Romiplostim||See Pricing||ALK and NTRK1 fusion molecules and uses thereof||FOUNDATION MEDICINE, INC. (Cambridge, MA)||See Pricing|
|Romiplostim||See Pricing||B7 family member zB7H6 and related compositions and methods||Zymogenetics, Inc. (Princeton, NJ)||See Pricing|
|Romiplostim||See Pricing||Trilayer coated pharmaceutical packaging||SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|